Encetron-SOLOpharm oral solution 100mg/ml 10ml, 10pcs

Composition

>

1 ml of the drug contains:

Active ingredient:

Citicoline sodium 104.5 mg

in terms of citicoline 100.0 mg

Auxiliary substances:

Sorbitol liquid (non-crystallizing) 200.0 mg

Glycerol anhydrous 50.0 mg

Sodium Citrate Dihydrate 6.0 mg

Citric Acid Anhydrous to pH 5.0-7.0

Water for injection up to 1.0 ml

Pharmacological action

Citicoline is a natural endogenous compound that is an intermediate metabolite in the synthesis of phosphatidylcholine, one of the main structural components of the cell membrane. Citicoline has a broad spectrum of action: It helps restore damaged cell membranes, inhibits the action of phospholipases, prevents excessive formation of free radicals, and also prevents cell death by affecting the mechanisms of apoptosis. In the acute period of stroke, citicoline reduces the amount of damage to brain tissue, improves cholinergic transmission. With traumatic brain injury, it reduces the duration of post-traumatic coma and the severity of neurological symptoms, in addition, it helps to reduce the duration of the recovery period. In chronic brain hypoxia, citicoline is effective in treating cognitive disorders such as memory loss, lack of initiative, difficulties in performing daily activities and self-care. Increases the level of attention and consciousness, and also reduces the manifestation of amnesia. Citicoline is effective in the treatment of sensory and motor neurological disorders of degenerative and vascular etiology.

Indications

– Acute period of ischemic stroke (as part of complex therapy).

– Recovery period of ischemic and hemorrhagic strokes.

– Traumatic brain injury, acute (as part of complex therapy) and recovery period.

– Cognitive and behavioral disorders in degenerative and vascular diseases of the brain.

Recommendations for use

Solution for oral use, used orally.

Before use, the drug can be diluted in a small amount of water (100-120 ml or 1/2 cup). Take with meals or between meals.

Recommended dosage regimen

Acute period of ischemic stroke or traumatic brain injury (TBI):  1000 mg (10 ml) every 12 hours. The duration of treatment is at least 6 weeks.

Recovery period of ischemic and hemorrhagic strokes, recovery period of TBI, cognitive and behavioral disorders in degenerative and vascular diseases of the brain: 500-2000 mg (5-20 ml) per day. Dosage and duration of treatment – depending on the severity of the symptoms of the disease.

Elderly patients

When prescribing citicoline to elderly patients, no dose adjustment is required.

Contraindications

-Hypersensitivity to any of the components of the drug.

– Do not prescribe to patients with severe vagotonia (high tone of the parasympathetic part of the autonomic nervous system).

– Due to the lack of sufficient clinical data, it is not recommended to use in children under 18 years of age.

Side effects

Side effects are grouped by frequency of occurrence: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1000 to < 1/100), rare (≥ 1/10000 to < 1/1000), very rare (Very rare (:  allergic reactions (rash, pruritus, anaphylactic shock), headache, dizziness, feeling hot. Tremors, nausea, vomiting, diarrhea, hallucinations, edema, shortness of breath, insomnia, agitation, decreased appetite, numbness in paralyzed limbs, changes in the activity of liver enzymes. In some cases, citicoline can stimulate the parasympathetic system, as well as have a short-term change in blood pressure. If any of the side effects listed in the instructions get worse or you notice any other side effects not listed in the instructions, tell your doctor.

The interaction of

Citicoline enhances the effects of levodopa. Do not use concomitantly with medications containing meclofenoxate.

Overdose

Taking into account the low toxicity of the drug, cases of overdose are not described, even if the therapeutic doses are exceeded.

Functional features

Absorption Citicoline is well absorbed when taken orally. Absorption after oral use is almost complete, and bioavailability is almost the same as after intravenous use. Metabolism Citicoline is metabolized in the intestines and liver to form choline and cytidine. After use, the concentration of choline in the blood plasma increases significantly. Distribution Cyticoline is largely distributed in brain structures, with rapid incorporation of choline fractions into structural phospholipids and cytidine fractions into cytidine nucleotides and nucleic acids. After reaching the brain, citicoline is embedded in cellular, cytoplasmic and mitochondrial membranes, taking part in the construction of the phospholipid fraction. Excretion Only 15% of the administered dose of citicoline is excreted from the human body: less than 3% – by the kidneys and about 12% – with exhaled mucus. In the excretion of the drug in the urine, there are two phases: the first phase – about 36 hours, in which the rate of elimination decreases rapidly, and the second phase, in which the rate of elimination decreases much more slowly. The same phasicity is observed with CO 2 excretion, the rate of exhaled CO 2 excretion decreases rapidly after about 15 hours, and then it decreases much more slowly.

Storage conditions

At a temperature not exceeding 30 °C.

Keep out of reach of children.

Shelf

life is 3 years.

Do not use after the expiration date!

Active ingredient

Citicoline

Conditions of release from pharmacies

By prescription

Dosage form

oral solution